Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 28 Carcinoma, Renal Cell 19 Carcinoma, Non-Small-Cell Lung 13 Carcinoma, Hepatocellular 10 Brain Neoplasms 7 Skin Neoplasms 6 Neoplasm Metastasis 6 Clear-cell metastatic renal cell carcinoma 6 Neoplasms 5 Kidney Neoplasms 5 Colorectal Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 4 Lung Neoplasms 4 Carcinoma, Transitional Cell 4 Triple Negative Breast Neoplasms 3 Multiple Myeloma 3 Mesothelioma 3 Liver Neoplasms 3 Breast Neoplasms 3 Uveal Melanoma 2 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 Mesothelioma, Malignant 2 Lymphoma, Non-Hodgkin 2 Glioblastoma 2 Colonic Neoplasms 2

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma, Cutaneous Malignant × Ipilimumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡